Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002216 · ClinicalTrials.gov registry record · NA

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

A NA study of HIV Infections, sponsored by Glaxo Wellcome.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002216 is a NA study of HIV Infections that has completed, run by Glaxo Wellcome. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002216, a NA study of HIV Infections, has completed, sponsored by Glaxo Wellcome.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.

Conditions Studied

HIV Infections

Interventions

  • DRUG Nelfinavir mesylate
  • DRUG Lamivudine/Zidovudine
  • DRUG Abacavir sulfate
  • DRUG Amprenavir

Study Locations (1)

Pennsylvania

  • Anderson Clinical Research - Pittsburgh

Trial Details

FieldValue
Phase NA

Sponsor

Glaxo Wellcome

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002216

The ClinicalTrials.gov registry entry for NCT00002216 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Nelfinavir mesylate is the first listed.

NCT00002216 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00002216 about?

NCT00002216 is a clinical study titled "A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment". The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.

What is the current status of trial NCT00002216?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002216 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002216?

The interventions under investigation include: Nelfinavir mesylate (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG), Amprenavir (DRUG).

Who is sponsoring clinical trial NCT00002216?

This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002216 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.